At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial
In Brief
A Phase 3 clinical trial evaluating Standardized Brazilian Green Propolis Extract and Placebo for Covid19 and Inflammation. Completed, enrolled 200 participants across 1 site.
Detailed Summary
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Among candidate adjunct treatment options, propolis, produced by honey bees from bioactive plant exudates, has shown potential against viral targets and has demonstrated immunoregulatory properties.
Study Details
Timeline
Interventions
900mg/day of Standardized Brazilian Green Propolis Extract for 10 days.
900mg/day of Placebo for 10 days.